Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Marina Konopleva et al.|New England Journal of Medicine|2019Cited by 502
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeChristine M. Parseghian, Scott Kopetz, Jonathan M. Loree et al.|Annals of Oncology|2018Cited by 239
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal AdenocarcinomaEugene J. Koay, Jason B. Fleming, Yeon‐Ju Lee et al.|Clinical Cancer Research|2018Cited by 111
Evolution of Measurement System and SI Units in IndiaShanay Rab, D. K. Aswal, Sanjay Yadav et al.|MAPAN|2020Cited by 50
Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemiaNitin Jain, William G. Wierda, Varsha Gandhi et al.|Blood|2025Cited by 3